Navigation Links
Arpida Reports Interim Results For Six Months to 30 June 2009
Date:8/19/2009

REINACH, Switzerland, August 19 /PRNewswire-FirstCall/ -- Arpida Ltd (SIX: ARPN) announced today its financial results for the six months ending 30 June 2009.

    Key events 2009 to date

    - Regulatory setback for intravenous iclaprim in cSSSI in U.S.A.
    - Strategic options under review
    - Company restructuring completed

Cash and financial investments of CHF 22.7 million at 30 June 2009

CFO Harry Welten, MBA, commented: "Our cost-saving measures have been implemented, resulting in a substantial reduction of the cash burn. We expect to have cash and financial investments of around CHF 14 million at the end of 2009."

Dr Jurgen Raths, President and CEO, commented: "Arpida is going through challenging times. We've completed a painful restructuring process in anticipation of a possible strategic deal. We remain fully committed to finding a strategic partner and securing the maximum value for our shareholders. Discussions are ongoing, as soon as these advance, we will provide an update."

The full 10 page text is available under: http://www.arpida.com

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

    Contacts:

    Dr Jurgen Raths, President and CEO
    Tel: +41-61-417-96-60

    Harry Welten, MBA, CFO and Senior Vice President
    Tel: +41-61-417-96-65

    Paul Verbraeken, Head of Corporate Communications
    Tel: +41-61-417-96-83


'/>"/>
SOURCE Arpida Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Arpida Annual General Meeting of Shareholders Approves All Board Proposals
2. Arpida to Discuss Strategy With Shareholders
3. Arpida Announces Full Year 2008 Financial Results
4. Arpida to Restructure and Focus on Key Projects
5. Arpidas iclaprim MAA Accepted for Review by EMEA
6. Arpida Reports Interim Results for Six Months to 30 June 2008
7. Arpida Announces FDA Acceptance of the Iclaprim New Drug Application
8. Arpida Annual General Meeting of Shareholders Approves All Board Proposals
9. Leadership Change to Enable Arpida to Become a Fully Integrated Pharmaceutical Company
10. Arpida Announces Conference Call on 17 April
11. Arpida Announces Agenda Items for Shareholders Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... ... , ... Over 8,000 recognized rare diseases afflict an estimated 350 million people ... March 7, DrugDev will gather international experts to share challenges and provide insight and ... Overcoming the Challenges of Rare Disease Clinical Trials, Date: March 7, 2017, Time: 10:00-11:00 ...
(Date:2/28/2017)... , ... February 28, 2017 , ... ... discovery of antibody therapeutics from millions-diverse immune repertoires, today announced a strategic partnership ... mouse strains genetically engineered to express human antibodies. The partnership will use GigaGen ...
(Date:2/28/2017)... PHILADELPHIA , Feb. 28, 2017 ... company focusing on debilitating diseases including rare genetic diseases ... the company joins with the National Organization for Rare ... support around the world in commemorating Rare Disease Day, ... and needs of the millions of patients and families ...
(Date:2/28/2017)... VANCOUVER , Feb. 28, 2017 /PRNewswire/ - RepliCel ... "Company"), a clinical stage regenerative medicine company developing unique ... and sun-damaged skin, and chronic tendon degeneration, today announced ... both of whom have committed to work with RepliCel ... manufactured and tested. ...
Breaking Biology Technology:
(Date:2/1/2017)... , February 1, 2017 IDTechEx Research, a ... emerging technology, announces the availability of a new report, Sensors ... Continue Reading ... ... and collaborative robots. Source: IDTechEx Report "Sensors for Robotics: Technologies, Markets ...
(Date:1/30/2017)... --  Invitae Corporation (NYSE: NVTA ), ... announced that it will report its fourth quarter and ... Monday, February 13, 2017, and Invitae,s management team will ... Eastern / 1:45 p.m. Pacific. During ... results, guidance, and recent developments and will spend the ...
(Date:1/26/2017)... Jan. 26, 2017  Acuity Market Intelligence today ... and Digital Identity".  Acuity characterizes 2017 as a ... increased adoption reflects a new understanding of the ... "Biometrics and digital identity are often perceived as ... Most , Principal of Acuity Market intelligence. "However, ...
Breaking Biology News(10 mins):